NEW YORK – Nanomix said Friday that under a new agreement the Mast Group would market and distribute Nanomix's eLab handheld electrochemical analyzer and infection panels in the UK, France, Germany, Ireland, and South Africa.
San Leandro, California-based Nanomix said the deal with UK-based Mast Group is Nanomix's largest expansion in the European market to date.
The Nanomix eLab system is a handheld immunoassay and chemistry diagnostic instrument for point-of-care testing.
"The Nanomix solution is a unique, breakthrough technology that offers mobile, timely diagnostic capability from a whole-blood sample," Nanomix CEO Thomas Schlumpberger said in a statement. "The eLab system will help expedite sepsis and pneumonia diagnosis leading to more informed treatment decisions, thus improving patient outcomes and hospital clinical collaboration."
Financial and other terms of the deal were not disclosed. Nanomix has been working this year to commercialize its immunoassay analyzer and critical infection test panel and previously announced agreements to distribute the analyzer and S1 infection panel in Israel and the Middle East.
Sandy Daun, sales and marketing director of the Mast Group, said that beginning this long-term, strategic relationship with Nanomix reinforces Mast's commitment to offer innovative diagnostic products, and Nanomix's technology provides a foundation to expand assay sales.